MRTO4

Across TCGA pan-cancer cohorts, MRTO4 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated MRTO4 data layer compared with 26 for mass-spec protein and 3 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher MRTO4 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated MRTO4 expression acts as an unfavorable survival marker, although some lineages such as LSCC show a favorable association.

CCRCC, LSCC, and HNSC are the cancer types where MRTO4 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Median	All	0.597	0.875	<.001	71	view →
LSCC	DFS	Tertile	II,III,IV	0.915	0.514	.001	38	view →
HNSC	DFS	Median	III,IV	0.695	0.877	.009	34	view →
PDAC	DFS	Median	III,IV	0.357	0.707	.018	8	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

MRTO4–CCRCC (DFS)

Open the CCRCC breakdown →